# Sutro Biopharma (STRO) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/STRO
## Company Profile
- Ticker: STRO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: ADCs, Oncology
## Stock Data
- Close: 25.04 USD
- Market cap: 404815824.77 USD
- Last updated: 2026-08-11
## Business Overview
### Next-Generation ADC Company
Sutro Biopharma develops site-specific and novel-format antibody-drug conjugates for cancer. Its cell-free platform enables optimization of antibodies, linkers, and payloads and supports both single-payload and dual-payload ADC designs.
### Wholly Owned ADC Pipeline
STRO-004 is a Tissue Factor-targeting ADC with a DAR8 topoisomerase I payload in a first-in-human Phase 1 dose-escalation study. STRO-006 targets ITGB6, while STRO-227 is a dual-payload ADC directed against PTK7.
### Portfolio and Partnership Model
Sutro advances wholly owned ADCs while using partnerships to validate and monetize its technology. Collaborations provide external funding and potential milestone or royalty economics while the company retains direct ownership of selected oncology programs.
### Cell-Free Platform Differentiation
The cell-free manufacturing system allows precise placement of non-natural amino acids and controlled attachment of linker-payload combinations. This capability supports consistent site-specific ADCs and formats that are difficult to generate through conventional cell-based expression.
### Partnered Platform Validation
The first dual-payload immune-stimulating ADC developed through Sutro’s collaboration with Astellas has entered clinical development and begun patient dosing, providing external validation of the company’s multi-payload design capabilities.
## Why The Stock Is Moving

As of Aug 11, 2026, STRO closed down 1.92% at $25.04. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initial safety, pharmacokinetic, and early activity data from the Phase 1 dose-escalation study of STRO-004 were expected in mid-2026.
- An IND submission for STRO-006 is planned in 2026.
- An IND submission for STRO-227 is planned in 2026.

## Recent News
- 2026-05-14 20:05 EST — [Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-first-quarter-2026-financial-results-and-business-highli-43d18eb3) — Source: Sutro Biopharma
- 2026-04-19 23:45 EST — [Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026](https://biopharmsignal.com/news/STRO/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next--bdf8f4ce) — Source: Sutro Biopharma
- 2026-03-23 20:05 EST — [Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-full-year-2025-financial-results-and-business-highlights-c81ab4c5) — Source: Sutro Biopharma
- 2026-02-25 13:30 EST — [Sutro Biopharma to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/STRO/sutro-biopharma-to-participate-in-upcoming-investor-conferences-5470cd63) — Source: Sutro Biopharma
- 2026-02-23 13:30 EST — [Sutro Biopharma Announces Participation at the 16th World ADC London Summit](https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-participation-at-the-16th-world-adc-london-summit-c229d910) — Source: Sutro Biopharma